VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | ALS and FTD: current treatment landscape

Yuliya Shpilyukova • 17 May 2020
EAN 2020
Amyotrophic Lateral Sclerosis Dementia Edaravone Riluzole
Treatment

Yuliya Shpilyukova, MD, Research Center of Neurology, Moscow, Russia, discusses the current treatment options for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Yuliya Shpilyukova

1:51
ALS and FTD future research
Yuliya Shpilyukova • 17 May 2020
2:31
C9orf72 hexanucleotide repeat expansion in ALS and FTD
Yuliya Shpilyukova • 17 May 2020

Related Videos

1:02
Treating Parkinson's disease dementia: challenges and progress
Stephen Pasternak • 29 Aug 2023
8:13
The potential of ambroxol in Parkinson’s disease dementia: Phase II trial results
Stephen Pasternak • 29 Aug 2023
2:20
How could AI have a meaningful impact in real world neurology?
Stephen Auger • 3 Jul 2023
2:38
The effect of cardiovascular risk factors and NOTCH3 variant position on the CADASIL phenotype
Nicola Rifino • 2 Jul 2023
The content of VJNeurology is intended for healthcare professionals